Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2002 Aug 3;325(7358):231-2.
doi: 10.1136/bmj.325.7358.231.

Continuous combined hormone replacement therapy and endometrial hyperplasia

David F Archer
Editorial

Continuous combined hormone replacement therapy and endometrial hyperplasia

David F Archer. BMJ. .
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

    1. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997;349:458–461. - PubMed
    1. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91:1131–1137. - PubMed
    1. Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000;183:1456–1461. - PubMed
    1. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;2:CD000402. - PubMed
    1. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;275:370–375. - PubMed

MeSH terms